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High-sensitivity TnT (hsTnT) has been proposed to improve the diagnosis and stratiﬁcation in acute coronary syndromes.
Copeptin has been proposed for a rapid and accurate rule out of acute myocardial infarction, but some doubts exist about its use
out of the ﬁrst hours from admission. Abnormalities of serum hsTnT and copeptin levels in non-STEACS and negative TnT, could
have prognostic implications. Methods. We included 122 non-STEACS patients without raised TnT, 33 disease controls and 43
healthy controls. We measured hsTnT and copeptin levels. Clinical follow-up at 12 months was performed for adverse endpoints.
Results. Non-STEACS patients had raised hsTnT compared with both control groups (P = 0.036 and P<0.001). Copeptin levels
were higher in non-STEACS patients than healthy controls (P = 0.021), without diﬀerences with disease controls. Raised levels of
hs-TnT presented prognostic implications [HR 3.29 (95%CI: 1.33–7.49), P = 0.010]. hs-TnT could be used for invasive approach
decision, as it shows prognostic relevance in conservative approach-patients whereas remains unrelevant for catheterized-patients.
Copeptin levels were not associated with adverse events. Conclusion. hsTnT levels increased in non-STEACS, were predictive
of adverse events and could be important for recommending an invasive management. We cannot conﬁrm a predictive role of
copeptin out of the ﬁrst hours from admission.
1.Introduction
Acute coronary syndromes (ACSs) present a complex and
heterogeneous pathophysiology [1–3] with high morbidity
and mortality mainly due to new cardiac ischaemic events
[4]. Current stratiﬁcation of the risk in patients presenting
with ACS without ST-segment elevation (non-STEACS) is
based on the identiﬁcation of those patients with higher risk
of suﬀering adverse events (death, recurrent MI or urgent
revascularization), estimated in a 15–30% of non-STEACS
patients. However, up to 10% of patients who classiﬁed as
low risk show a cardiovascular event at 3 months followup
[5]. Regarding this, the current stratiﬁcation needs to be
improved. It has been proposed to identify new biomarkers
or even to use a multimarker approach [6].
Cardiac troponins are components of the contractile
apparatus of cardiomyocytes and are released during my-
ocardial necrosis in patients with ACS [7]. Serum troponin
(Tn) elevation is a speciﬁc and well-established necrosis
biomarker in ACS, being the only biomarker currently used
for risk stratiﬁcation and guided invasive management deci-
sion in non-STEACS [8, 9]. In patients showing negative Tn
elevation, stratiﬁcation is more complicated and the elec-tive
treatment is usually under the criterium of the car-diologist,
although there are established recommendations [10, 11].
Conventional determination methods fail to detect slightly2 The Scientiﬁc World Journal
increases of Tn, due in part to the delayed and progressive
release of the biomarker after the event. It has been shown
that even very small elevation in the troponin concentration
is associated with increased risk of adverse outcomes in
patients with ACS [12]. A recent publication has shown
thatcardiactroponinT(TnT)concentrationsmeasuredwith
a highly sensitive assay were signiﬁcantly associated with
the incidence of cardiovascular death and heart failure in
stable coronary artery disease after adjustment for other
independent prognostic indicators [13]. In the same way,
Reichlin et al. found that the diagnostic performance of
sensitivity cardiac Tn assays is excellent within the context of
the myocardial infarction, and these assays can substantially
improve the early diagnosis of acute myocardial infarction,
particularly in patients with a recent onset of chest pain [14].
However, the criteria deﬁning a high sensitive TnT (hsTnT)
assay are still under debate, whereas a cutoﬀ point of TnT
for risk stratiﬁcation in patients with ACS remains diﬃcult
to establish due to the heterogeneity of the used detection
techniques among diﬀerent laboratories [15].
As the released of the necrosis markers after cell damage
might explain the weakness in diagnostic performance of
conventional Tn assays early after chest pain onset, markers
with diﬀerent pathophysiologic background independent of
cell necrosis might help in the diagnosis of cardiovascular
diseases [16]. Arginine vasopressin (AVP), also known as
the antidiuretic hormone, is a peptide secreted neurohy-
pophyseal hormone and controls osmotic homeostasis [17].
However, vasopressin is diﬃcult to measure because it is
unstable and rapidly cleared [18]. Copeptin, a 39-amino acid
glycopeptides that comprises the C-terminal part of the AVP
precursor, was found to be a stable and sensitive surrogate
marker of AVP release. Copeptin is secreted in equimolar
amounts, and it can be quickly and reliably measured in
unprocessed plasma or serum. The predictive value of this
marker has been shown in coronary artery disease [19], and
it has been proposed to be of great value in the rapid rule
out of acute myocardial infarction used in combination with
TnT increased levels [20].
We hypothesized that the use of a marker of cardiac
necrosis determined by high sensitivity methods, such as
hsTnT, or a pathophysiologically diﬀerent biomarker reﬂect-
ing acute endogenous stress, such as copeptin, together with
the association to the classical clinical and electrocardio-
graphic parameters, might help to the better stratiﬁcation
and managements as well as in the prognosis of patients with
non-STEACS.
2. Methods
2.1. Patients Admission and Selection. We prospectively re-
cruited consecutive patients admitted with a ﬁnal diag-
nosis of non-STEACS in two tertiary hospitals. Blood
samples were collected for all patients within 48 hours
of hospital admission, and baseline clinical characteristics
were prospectively recorded. Serum TnT was measured at
admission using a commercially available third-generation
immunoassay (Elecsys troponin T STAT; Roche Diagnostics,
Mannheim, Germany). According to the manufacturers,
the lower limit of detection and the concentration with
≤10% precision were 0.01 and 0.035ng/mL for TnT. We
adopted the recommendations of the Joint Committee of
the American College of Cardiology and the European
Society of Cardiology [21] to establish the upper limit of
normal cutoﬀ value of 0.035ng/mL for TnT. All patients
included were stratiﬁed as intermediate or high risk by
2002 ACC/AHA Guidelines for Diagnostic and Treatment
Strategies in the Emergency Department for Patients with
ACS [22]. Patients with elevated conventional TnT (TnT
>0.035mg/mL), concomitant neoplastic, infectious, connec-
tive tissue, or inﬂammatory diseases were excluded (n = 74).
During the entire hospitalization period, all patients
received standard management as recommended for ACS
[10, 23] and clinical management decisions about each
patientweredecidedbythecardiologistresponsible,whowas
unaware of the patient’s hsTnT and copeptin concentrations.
Patients with non-STEACS were compared with a group
of subjects with stable coronary artery disease (CAD),
deﬁned as patients with previous (>6 months) ST elevation
myocardial infarct, non-ST elevation myocardial infarct
or stable angina, without anginal symptoms for at least
2 months or negative treadmill test at the same time,
recruited from consecutive subjects in our outpatient clinics.
In addition, we recruited “healthy controls” consisted of
hospital staﬀ and relatives, who were deﬁned as “healthy”
by careful clinical history and physical examination, ECG,
and routine blood tests. The Research Ethics Commitee of
our two centres approved the study, and all the subjects gave
informed consent to participation.
2.2. Blood Samples and Laboratory Assays. Venepuncture
was performed within 48 hours of hospital admission,
usually the next morning with the patient fasting for >12
hours. In patients with stable CAD and healthy controls,
blood samples were taken after overnight fasting and
abstinence from tobacco, alcoholic, or caﬀeine-containing
beverages the evening before. Serum fractions were obtained
by centrifugation for 15 minutes at 3500g. Aliquots were
stored at −40◦C to allow batch analysis in a blinded fash-
ion. Serum levels of hsTnT were assayed by a Cobas
6000 analyser (Roche Diagnostics, Mannheim, Germany).
The interassay variation for hsTnT determining was 2.4%,
with a lower detection limit of 0.003ng/mL. We used the
established hsTnT cutoﬀ point in ACS in the literature,
0.013ng/mL [24]. We also determined copeptin in serum
by sandwich immunoluminometric assay (CT-proAVP LIA
B.R.A.H.M.S. AG, Hennigsdor, Germany). The detection
limit was 0.4pmol/L and the interassay variation coeﬃcient
<20%.
2.3. Followup and Adverse Clinical Endpoints. All patients
were followed for 12 months by outpatient clinic attendance,
telephone contact, and review of the medical notes. We
deﬁned “adverse clinical endpoints” as cardiovascular death
(death in context of ischaemic or other heart disease, of
death with unexplained cause, presumed cardiac), nonfatalThe Scientiﬁc World Journal 3
MI, unstable angina and stroke, and/or admission for acute
heart failure.
2.4. Statistical Analysis. Continuous variables were tested
for normal distribution by the Kolmogorov-Smirnov test.
The normal distributed continuous variables are shown as
mean ± standard deviation, and those nonparametrically
distributed are shown as median (interquartile range).
Categorical variables are presented as frequencies (percent-
ages). Comparisons of the groups for continuous variables
were performed with the unpaired t-test for independent
samples or the Mann-Whitney U test (as appropriate).
The comparison of discrete variables was done by χ2 test
or Fisher test (as appropriate). Correlation between two
continuous variables was performed using the Spearman
test. An ANOVA test (if relevant a Kruskall Wallis test)
was performed to assess the diﬀerences between biological
markers and analysed subject groups. In addition, multiple
binarylogisticregressionanalyseswereusedtodeterminethe
clinical and biological factors associated with the presence
of elevated biomarkers (levels above their cutoﬀ point).
The independent eﬀect of variables on prognosis was cal-
culated using a Cox proportional hazards regression model,
incorporating in the multivariate model only those variables
that showed P value < 0.15 in the univariate analysis. The
cumulative incidence of adverse clinical events was estimated
according to the Kaplan-Meier method, and the log-rank
statistic was used for comparisons. A P<0.05 was accepted
as statistically signiﬁcant. Statistical analysis was performed
using SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL, USA).
3. Results
A total of 198 subjects were included for the analyses: 122
patients with non-STEACS and conventional TnT levels ≤
0.035mg/mL, 33 patients with stable CAD, and 43 healthy
controls. The distribution of clinical characteristics and
laboratory parameters are listed in Table 1.
3.1. HsTnT. Patients with non-STEACS presented higher
serum hsTnT than those with stable CAD and healthy
controls [0.010 (0.005–0.023) versus 0.008 (0.005–0.011);
P = 0.036 and 0.010 (0.005–0.023) versus 0.004 (0.003–
0.007); P<0.001, resp.)] (Table 1, Figure 1). There was
a positive correlation between hsTnT levels and TIMI risk
score (Spearman, r = 0.39 P<0.001). There were no
diﬀerences in hsTnT levels related to current medication on
hospital admission (all P values > 0.05, Table 2).
At 12 months of followup, 22 (18.0%) patients presented
adverse clinical events: 7 (5.7%) cardiovascular death, 3
(2.5%) nonfatal MI, 9 (7.4%) unstable angina, 2 (1.6%)
stroke, and 1 (0.8) heart failure. We found a signiﬁcant
association between presenting adverse events and showing
positive hsTnT levels [OR: 2.99, 95% IC (1.18–7.57); P =
0.021].
There was a signiﬁcant association between increased
hsTnT levels and presenting at least three cardiovascular risk
factors, age > 65 years, ST deviation in the ECG, female sex,
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Figure 1: hsTnT levels in non-STEACS, stable coronary disease
(disease controls) and healthy controls [values are median (IQR),
and non-STEACS: non-ST elevation acute coronary s´ ındrome, DC:
disease controls, HC: healthy controls]. P<0.001. [Values are
median, IQR, and error bars].
and angiographic severe lesions [OR = 4.19 (95% CI: 1.76–
9.96), P = 0.001; OR = 2.40 (95% CI: 1.21–5.12), P = 0.024;
OR = 5.60 (95% CI: 2.44–12.86), P<0.001; OR = 0.35 (95%
CI: 0.15–0.86, P = 0.022; OR = 5.54 (95% CI: 2.07–14.83),
P = 0.001, resp., Table 3]. In the multivariable analysis
ST deviation, presenting at least three cardiovascular risk
factors, ST deviation, female sex, and severe angiographic
lesions remained as independent associated variables with
increased hsTnT levels [OR = 3.79 (95% CI: 1.02–14.16),
P = 0.047; OR = 6.27 (95% CI: 1.98–19.89), P = 0.002; OR
= 0.17 (95% CI: 0.004–0.68), P = 0.013; OR = 6.41 (95% CI:
1.41–29.24), P = 0.016, resp., Table 3).
According to the established cutoﬀ point for hsTnT in
A C S( 0 . 0 1 3n g / m L ) ,w ep e r f o r m e du n i v a r i a b l eC o xr e g r e s -
sion analysis (Table 4). High serum hsTnT levels [HR 3.29
(95% CI: 1.33–8.11), P = 0.010], age >65 years [HR 3.15
(95% CI: 1.20–8.31), P = 0.020], and previous non-STEACS
[HR 4.35 (95% CI: 1.68–11.26), P = 0.002] were signiﬁcant
predictors of adverse outcomes. Kaplan Meier curves show
that those with hsTnT levels above the cutoﬀ point presented
a worse prognosis (log-rank test, P = 0.006; Figure 2). In
a multivariable Cox regression analysis, hsTnT and previous
non-STEACS remained as independent predictors of adverse
outcomes [HR 2.74 (95% CI: 1.08–6.95), P = 0.034; HR 4.02
(95% CI: 1.55–10.43), P = 0.004, resp.].
We also explored the prognostic implication of hsTnT
in the diﬀerent scenarios, invasive (64 patients) and con-
servative approach (58 patients). We found a very relevant
prognostic implication for hsTnT levels in patients with
the conservative approach [HR 11.45 (95% CI: 2.93–44.72),
P<0.001], remaining as independent prognostic factor after
multivariate analysis (Table 5), whereas this biomarker did
not present any relevant implication in the interventional
approachinwhomcoronarycatheterismwasperformed[HR
0.78 (95% CI: 0.20–3.14), P = 0.731]. In the multivariate
analysis, only high hsTnT levels and presenting previous4 The Scientiﬁc World Journal
Table 1: Baseline characteristics of patients and controls.
Non-STEACS Disease controls Healthy controls
N 122 33 43
Age (mean ± SD) 63.2 ±11.46 3 .9 ±12.76 6 .62 ±7.8
Male sex (%) 83 (68.0) 31 (93.9) 17 (39.5)
Hypertension (%) 92 (75.4) 26 (78.8) 23 (53.5)
Diabetes mellitus (%) 40 (32.8) 14 (42.4) 10 (23.3)
Hypercholesterolemia (%) 67 (54.9) 20 (60.6) 11 (25.6)
Smoking habit (%) 27 (22.1) — —
Medications ——
Aspirin (%) 120 (98.4) — —
Clopidogrel (%) 120 (98.4) — —
ARBs (%) 34 (27.9) — —
Beta-blocker (%) 50 (41.0) — —
ACE inhibitors (%) 33 (27) — —
CA (%) 25 (20.5) — —
Statins (%) 64 (52.0) — —
ST deviation (%) 39 (32) — —
TIMI risk score (mean ± SD) 2.04 ±1.31 — —
Catheterism (%) 64 (52.5)
Stent carrier (%) 54 (43.9)
hsTnT (ng/mL) 0.010 (0.005–0.023) 0.008 (0.005–0.011) 0.004 (0.003–0.007)
Copeptin >14pmol/mL (%) 10 (8.2) 4 (12.1) 1 (2.3)
Copeptin (pmol/L) 8.42 (5.60–13.35) 11.67 (7.08–14.56) 6.51 (4.80–9.08)
High-sensitivity troponin T (hsTnT) and copeptin levels data shown as median (IQR). NSTEACS: non ST-elevation acute coronary syndrome; ARBs:
angiotensin receptor blockers; ACE: angiotensin-converting enzyme; CA: calcium antagonists.
Table 2: hsTnT levels in relation to diﬀerent modalities of drug therapy.
Therapy hsTnT levels (ng/mL) P value
Aspirin Yes: 0.014 (0.007–0.027) 0.583
No: 0.008 (0.008–0.008)
Clopidogrel Yes: 0.013 (0.001–0.026) 0.383
No: 0.029 (0.029–0.029)
ARBs Yes: 0.009 (0.004–0.016) 0.557
No: 0.010 (0.005–0.026)
Beta-blocker Yes: 0.011 (0.005–0.026) 0.478
No: 0.009 (0.004–0.021)
ACE inhibitors Yes: 0.010 (0.005–0.023) 0.771
No: 0.009 (0.005–0.024)
CA Yes: 0.012 (0.007–0.023) 0.370
No: 0.009 (0.004–0.021)
Statins Yes: 0.013 (0.005–0.029) 0.087
No: 0.009 (0.004–0.029)
Values are median (IQR). ARBs: angiotensin receptor blockers; ACE: angiotensin-converting enzyme; CA: calcium antagonists.
non-STEACS remained as independent predictors of adverse
outcomes at 12-month followup [HR 6.20 (95% CI: 1.31–
29.27), P = 0.021; HR 12.00 (95% CI: 1.43–100.52), P =
0.022, resp.].
3.2. Copeptin. Copeptin levels were signiﬁcantly higher in
non-STEACS patients than healthy controls (P = 0.021),
without diﬀerences with disease controls (P = 0.186). This
biomarker did not show any correlation to classical TnT
values obtained at admission (Spearman, r = 0.006, P =
0.951). Copeptin levels also were not found to be correlated
to TIMI risk score (Spearman, r =− 0.102, P = 0.318).
We did not ﬁnd signiﬁcant association between increased
Copeptin levels (above cutoﬀ point of 14pmol/L) and any ofThe Scientiﬁc World Journal 5
Table 3: Association of elevated hsTnT levels with clinical features. Logistic regression analyses. Cutoﬀ point for hsTnT = 0.013ng/mL.
Univariate Multivariate
Condition OR (95% CI) P OR (95% CI) P
age > 65 years 2.40 (1.21–5.12) 0.024 2.42 (0.78–7.53) 0.127
Previous non-STEACS 1.84 (0.69–4.86) 0.221
Female sex 0.35 (0.15–0.86) 0.022 0.17 (0.04–0.68) 0.013
≥3 CVRF 4.19 (1.76–9.96) 0.001 3.79 (1.02–14.16) 0.047
Previous ASA taking 1.92 (0.89–4.15) 0.097 0.92 (0.26–3.29) 0.893
Severe symptoms 0.64 (0.31–1.55) 0.396
ST deviation 5.60 (2.44–12.86) <0.001 6.27 (1.98–19.89) 0.002
PCI at admission 1.92 (0.90–4.10) 0.094 2.65 (0.75–9.37) 0.131
Angiographic lesions >50% 5.54 (2.07–14.83) 0.001 6.41 (1.41–29.24) 0.016
Previous non-STEACS: Previous non-ST elevation acute coronary syndrome. ≥3 CVRF: at least three cardiovascular risk factors. ASA: acetylsalicylic acid.
OR: odds ratio. CI: conﬁdence interval. PCI: percutaneous coronary intervention.
Table 4: Cox regression analysis at 12-month followup.
Univariate Multivariate∗
Condition HR (95% CI) P HR (95% CI) P
hsTnT>0.013ng/mL 3.29 (1.33–8.11) 0.010 2.74 (1.08–6.95) 0.034
Copeptin > 14pmol/L 0.04 (0.00–14.78) 0.285
age > 65 years 3.15 (1.20–8.31) 0.020 2.52 (0.88–7.21) 0.111
Severe symptoms 1.65 (0.65–4.17) 0.294
≥3 CVRF 2.00 (0.75–5.32) 0.167
Previous non-STEACS 4.35 (1.68–11.26) 0.002 4.02 (1.55–10.43) 0.004
ST deviation 1.14 (0.32–3.95) 0.841
∗Multivariate analysis by conditional method. ≥3 CVRF: at least three cardiovascular risk factors. Previous non-STEACS: previous non-ST elevation acute
coronary syndrome. HR: hazard ratio. CI: conﬁdence interval.
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Figure 2: Kaplan-Meier curve showing the eﬀects of hsTnT levels
on adverse events following in non-STEACS patients. Patients with
raised hs TnT levels, had a signiﬁcant worse outcome compared
with patients with lower hsTnT levels at 12-month followup (cutoﬀ
point >0.0013ng/mL; log-rank test, P = 0.06).
the studied clinical variables, and Cox analyses did not reveal
Copeptin as a signiﬁcant predictor in non-STEACS patients
(Table 4) nor in patients undergoing conservative approach
(Table 5).
4. Discussion
Although many biomarkers have been investigated in recent
years to be used for risk stratiﬁcation in ACS, cardiac Tn
still remains as the preferred and really used biomarker
for routine diﬀerential cardiovascular diagnosis [8, 9, 25].
Cardiac Tn measured by automated standard assays is
superior to all other available biomarkers in clinical practice,
including myoglobin, the MB fraction of creatine kinase,
myeloperoxidase, and heart fatty acid-binding protein, for
the diagnosis of acute myocardial infarction [26–28]. How-
ever, a considerable number of patients cannot still be
identiﬁed as being at high risk by available routine biomark-
ers. New high-sensitive cardiac Tn assays have improved
precision at the lower limit of detection and have been
shown to be very useful in the early diagnosis of acute
myocardial infarction [14], but there is a strong debate about
theclinicaluseandlimitationsofthesenewTnhigh-sensitive
detection methods [22, 29, 30]. A recent study by Bonaca et
al. showed that low-level increases in Tn I using a sensitive
assay identify patients at higher risk of death or MI among
patients with non-STEACS, as a probe of the incremental
value of newer, more sensitive assays in identifying high-risk
patients with ACS [31]. Our hypothesis is that serum hsTnT
levels could play an important role for risk stratiﬁcation,
therapeutic decision-making, and prognosis in non-STEACS
patients.6 The Scientiﬁc World Journal
Table 5: Cox regression analysis at 12-month followup for patients without invasive catheterization (n = 58).
Univariate Multivariate
Condition HR (95% CI) P HR (95% CI) P
hsTnT>0.013ng/mL 11.45 (2.93–44.72) <0.001 6.20 (1.31–29.27) 0.021
age > 65 years 1.21 (0.35–4.20) 0.760
Copeptin > 14pmol/L 0.039 (0.00–95.09) 0.416
Severe symptoms 1.18 (0.27–4.74) 0.811
≥3 CVRF 3.67 (0.98–13.68) 0.053 1.39 (0.31–6.20) 0.667
Previous non-STEACS 17.53 (2.19–140.57) 0.007 12.00 (1.43–100.52) 0.022
ST deviation 2.78 (0.58–13.44) 0.202
≥3 CVRF: at least three cardiovascular risk factors. Previous non-STEACS: previous non-ST elevation acute coronary syndrome. HR: hazard ratio. CI:
conﬁdence interval.
The present study shows that patients with non-STEACS
and negative conventional TnT (>0.035ng/mL) present a
rate of 16% of adverse events, with a remarkable 4% rate of
death. This highlights that these apparently non- high-risk
patients actually require a better risk stratiﬁcation strategy.
Moreover, more than 60% of our included patients were
diagnosed with unstable angina or non-Q acute myocardial
infarction, pointing out the moderate risk character of
our selected population. These ﬁndings are in concordance
with those previously described in former studies including
similar patients proﬁles [32, 33]. In this sense, we show
that our non-STEACS patients present signiﬁcantly higher
levels of hsTnT than controls and chronic stable patients.
A recent and complete study by Reichlin et al. [14]r e v e a l s
that hs-Tn assays can substantially improve early diagnostic
and allow treatment options for patients presenting with
acute myocardial infarction. Now, we add important ﬁnd-
ings in the utility of hsTnT, as we propose that hsTnT
measurement allows the identiﬁcation and stratiﬁcation of
patients presenting with non-STEACS and provides relevant
information about the prognosis at 12-month followup.
Hence,wefoundthatpatientswithraisedserumhsTnTlevels
(above 0.013ng/mL) presented more adverse events than
those with lower hsTnT levels. Interestingly, raised hsTnT
levels maintained its independent prognostic value, together
with the ST deviation and previous aspirin treatment, even
after adjusting for other consistent variables. In addition,
we also show, for the ﬁrst time, that raised hsTnT levels
are independently associated with cardiovascular risk factors
andSTdeviationinnon-STEACSpatients,afteradjustingfor
other confounding variables which is of high relevance since
hsTnT could identify patients at higher risk of presenting
cardiovascular events.
Nowadays the therapeutic decision in non-STEACS is
still basically under the criterium of the cardiologist, al-
though guidelines and recommendations appear in continu-
ousrevisionoftheclinicalmanagementofthesepatients [10,
11]. In the same way, we propose that serum hsTnT levels
could help in this treatment decision, since in patients who
did not underwent catheterization, those showing high levels
of serum hsTnT (cut-oﬀ point 0.0225ng/mL) presented a
worse outcome. Furthermore, the established cutoﬀ point
0.0130ng/mL did not predict the outcome for these patients.
This emphasizes the utility of this biomarker, especially in
patients apparently not elective for cardiac catheterization
under classical stratiﬁcation, in which raised hsTnT levels
could be indicative for interventionism recommendation.
I no r d e rt oe v a l u a t et h eu s eo fb i o m a r k e r so fd i ﬀerent
pathophysiologicproﬁles,wealsotestedabiomarkerofacute
endogenous stress, copeptin. Copeptin was found to present
predictive value in coronary artery disease [19], and it has
been proposed to be of great value in the rapid rule out
of acute MI used in combination with TnT increased levels
[15, 19]. We also study the association between the classical
clinical and electrocardiographic parameters in order to
achieve a better stratiﬁcation and managements as well as
the prognosis of patients with non-STEACS. We detected
signiﬁcant higher serum copeptin concentration in non-
STEACS’ patients in comparison with healthy controls.
However, this diﬀerence was not signiﬁcant when comparing
with chronic stable patients. In addition, we were not able
to ﬁnd any signiﬁcant association with clinical parameters
or prognostic implications for serum copeptin. One possible
reason for the lack of relevant results with copeptin is its
rapid release after symptom onset and the normalization
of its levels to below the 99th percentile in 10 hours as
prevouslyreported[16,20].Sincewecollectedbloodsamples
within the ﬁrst 48h from the pain onset, it is possible
that in most of patients, copeptin detected levels did not
correspond with the real raised values within the ﬁrst four-
hour window. Additional studies should be done to clarify
copeptinrelevanceintheﬁrst6hfromthepainonsetinnon-
STEACS patients.
Our study has the important limitation of the measure-
ment of single baseline samples in determining prognosis.
Although hsTnT levels correlated with TIMI risk score and
seems to predict poor outcomes at 12-month followup, we
cannot discard changes in hsTnT levels during the time. In
addition, the size of our population can also limit the power
of our study. Bigger-sized studies are recommended but at
this point our data seems to be of great relevance. On the
other hand, copeptin levels should be measured within the
ﬁrst four hours form the pain onset in order to reevaluate its
clinical relevance in non-STEACS patients.The Scientiﬁc World Journal 7
5. Conclusion
In conclusion, serum hsTnT levels are signiﬁcantly increased
in non-STEACS patients and may be involved in the path-
ogenesis of this condition. High hsTnT levels improve dis-
criminationofpatientsatriskofadverseeventsarepredictive
of adverse events, and should be included in the therapeutic
decision-making.
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